Katja Weisel

Trial in Progress: Once-Weekly vs Twice-Weekly Dosing of Carfilzomib-Lenalidomide-Dexamethasone in Patients w/ Relapsed or Refractory Multiple Myeloma

Purpose of the Study: Carfilzomib (K), an irreversible proteasome inhibitor, is approved for the treatment of patients (pts) with relapsed or refractory  multiple  myeloma &nbsp...

Xavier Leleu ;

Meral Beksac ;

Maria-Victoria Mateos ;

Ludek Pour ;

Katja Weisel ;

Daniel Coriu ;

Mihaela Obreja ;

Amanda Goldrick ;

Meletios-Athanasios Dimopoulos ;

10/23/2019

Featured Webinar

Implementing ERAS Protocols Throughout Patient Peri-Op Journey: Reductions in Complications

Upcoming Events

November 23 ⁠–⁠ November 24

December 4 ⁠–⁠ December 5

Great Debates & Updates in Diabetic Foot

December 6 ⁠–⁠ December 7

December 9 ⁠–⁠ December 11

December 12 ⁠–⁠ December 13

December 14 ⁠–⁠ December 15

February 2 ⁠–⁠ February 5

February 27 ⁠–⁠ March 1

March 17 ⁠–⁠ March 19

See Full Calendar

Katja Weisel

Featured Webinar

Upcoming Events

Specialties

Events

Year Round Education

HMP Global Products